Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

About this update from Carlsmed, Inc.

[{"type":"image","alt":"Carlsmed","displaySize":"","headline":null,"caption":"Carlsmed","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cccd860298c64d0a18c1d7b3706250f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hS_gs.MQTCoePNI_FWsiww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cccd860298c64d0a18c1d7b3706250f7","width":282,"height":62}},"lazy":false},{"type":"text","content":"Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024","length":161,"tagName":"p"},{"type":"text","content":"CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and unaudited revenue for the fourth quarter and year ended December 31, 2025.","length":308,"tagName":"p"},{"type":"text","content":"Preliminary Q4 & FY 2025 Revenue Results ","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter 2025 revenue was approximately $15.2 million, an approximate 61% increase compared to the fourth quarter 2024.","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 revenue was approximately $50.5 million, an approximate 86% increase compared to the full year 2024.","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":240,"olType":false},{"type":"text","content":"“Our fourth quarter commercial performance capped a transformational year for Carlsmed and underscores the power of aprevo®. This platform technology provides surgeons with greater procedural predictability and has the potential to meaningfully improve clinical outcomes in spine fusion and lower the total cost of care for the healthcare system. With growing enthusiasm for aprevo®, we added 101 new surgeon users in 2025, representing a 61% increase in our total surgeon user base over the prior year,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “As we enter 2026, we are focused on executing our strategy for the next phase of growth with operational excellence. We are energized by the momentum in our business...

More updates from Carlsmed, Inc.